Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 55Carcinoma, Hepatocellular 40Neoplasms 38Polycystic Ovary Syndrome 27Colorectal Neoplasms 24Stomach Neoplasms 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Prostatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Recurrence 13Pancreatic Neoplasms 13Lymphoma 13Liver Neoplasms 13Urinary Bladder Neoplasms 11Leukemia, Myeloid, Acute 11Esophageal Neoplasms 11Leiomyoma 10Colonic Neoplasms 10Pain 9Lung Neoplasms 9Multiple Myeloma 8Uterine Cervical Neoplasms 7Neoplasm Metastasis 7Lymphoma, Non-Hodgkin 7Lymphoma, Follicular 7Keratosis, Actinic 7Infertility 7Papillomavirus Infections 6Pain, Postoperative 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6

Interventions

candesartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Unknown × Essential Hypertension × Clear all
NCT01629225 2014-11-18

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Phase 4 Unknown
500 enrolled
Endocrine

Essential Hypertension, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡